AR049275A1 - Derivados de camptotecina conjugada en posicion 20 con antagonistas de la integrina - Google Patents

Derivados de camptotecina conjugada en posicion 20 con antagonistas de la integrina

Info

Publication number
AR049275A1
AR049275A1 ARP050101933A ARP050101933A AR049275A1 AR 049275 A1 AR049275 A1 AR 049275A1 AR P050101933 A ARP050101933 A AR P050101933A AR P050101933 A ARP050101933 A AR P050101933A AR 049275 A1 AR049275 A1 AR 049275A1
Authority
AR
Argentina
Prior art keywords
group
linear
branched
alkyl
integer
Prior art date
Application number
ARP050101933A
Other languages
English (en)
Spanish (es)
Inventor
Pozzo Alma Dal
Ming Hong Ni
Sergio Penco
Lucio Merlini
Valle Sabrina Dalla
Giuseppe Giannini
Maria Ornella Tinti
Claudio Pisano
Domenico Alloatti
Loredana Vesci
Franco Zunino
Original Assignee
Sigma Tau Ind Farmaceuti
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti, Ist Naz Stud Cura Dei Tumori filed Critical Sigma Tau Ind Farmaceuti
Publication of AR049275A1 publication Critical patent/AR049275A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP050101933A 2004-05-13 2005-05-12 Derivados de camptotecina conjugada en posicion 20 con antagonistas de la integrina AR049275A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000241A ITRM20040241A1 (it) 2004-05-13 2004-05-13 Camptotecine coniugate in posizione 20 con antagonisti delle integrine.

Publications (1)

Publication Number Publication Date
AR049275A1 true AR049275A1 (es) 2006-07-12

Family

ID=35124307

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101933A AR049275A1 (es) 2004-05-13 2005-05-12 Derivados de camptotecina conjugada en posicion 20 con antagonistas de la integrina

Country Status (12)

Country Link
US (1) US20070232639A1 (enExample)
EP (1) EP1747019A2 (enExample)
JP (1) JP2007537244A (enExample)
CN (1) CN101010103A (enExample)
AR (1) AR049275A1 (enExample)
AU (1) AU2005243834A1 (enExample)
BR (1) BRPI0511037A (enExample)
CA (1) CA2562572A1 (enExample)
IT (1) ITRM20040241A1 (enExample)
MX (1) MXPA06012886A (enExample)
TW (1) TW200538125A (enExample)
WO (1) WO2005110487A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2606911A1 (en) * 2007-02-16 2013-06-26 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
MX2014008373A (es) * 2012-01-27 2014-09-26 Hoffmann La Roche Conjugados antagonistas de integrina para suministro dirigido a celulas que expresan alfa-v-beta-3.
CN105399757A (zh) * 2015-12-29 2016-03-16 遵义医学院 酸敏感型喜树碱-20位去甲斑蝥酸酯衍生物及其抗肿瘤应用
CN111068068A (zh) * 2019-12-04 2020-04-28 云南民族大学 一种rgd多肽-喜树碱多肽药物偶联物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815812A1 (de) * 1998-04-08 1999-10-14 Bayer Ag Modifizierte Cytostatika
ATE216998T1 (de) * 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
US6207832B1 (en) * 1999-04-09 2001-03-27 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
HUP0203899A3 (en) * 1999-09-08 2004-09-28 Bayer Ag Conjugates containing alphavbetha3 or alphavbetha5 integrin antagonist and cytostatic, process for their preparation and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
ITRM20040241A1 (it) 2004-08-13
US20070232639A1 (en) 2007-10-04
TW200538125A (en) 2005-12-01
EP1747019A2 (en) 2007-01-31
CN101010103A (zh) 2007-08-01
WO2005110487A3 (en) 2007-02-15
AU2005243834A1 (en) 2005-11-24
WO2005110487A2 (en) 2005-11-24
CA2562572A1 (en) 2005-11-24
JP2007537244A (ja) 2007-12-20
BRPI0511037A (pt) 2007-11-27
MXPA06012886A (es) 2007-02-15

Similar Documents

Publication Publication Date Title
AR048949A1 (es) Camptotecina conjugada en posicion 7 con antagonistas de la integrina
CY1111983T1 (el) Φαρμακευτικη συνθεση και μεθοδος χρησης αντιμυκητιακου παραγοντα σε συνδυασμο
AR037080A1 (es) Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios
BR0212910A (pt) aparelhos, dispositivo de fixação, áncoras, membro e métodos para reparação de tendão ou ligamento - incluido do tendão de aquiles e do manquito rotador - para carregamento, ligação e fixação de membro de retenção e de tendão ou ligamento ao osso - incluido do lábio do glenóide ao alvéolo do glenpoide- para ligação e fixação de tecido mole em tecido duro e ao osso e utensìlios de enrugamento e de recuperação
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR039540A1 (es) Compuestos microbicidas con contenido de pirimidina o triazina
PT2662448T (pt) Fosfatase alcalina dirigida ao osso, kits e métodos para a utilização da mesma
CO4340731A1 (es) Una combinacion farmaceutica de fluoxetina, venlafaxina, milnacipran o duloxetina, y un componente de alprenolol, way 100135, espiperona, pindolol, (s)-uh-301, penbutolol, pro- pranolol, tertatolol, y una ariloxipropanolamina
NO2011025I1 (no) Telavancin, eller et farmasøytisk aksseptabelt salt derav, herunder inkludert telavancin hydroklorid
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
CR9452A (es) Agentes terapeuticos a base de peptidos de toxinas
BRPI0513460A (pt) composição aquosa suave apropriada para a limpeza do cabelo e da pele
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
AR070587A1 (es) Composiciones efervescentes de limpieza y metodos de aplicacion
BR0116698A (pt) Composto de modafinila e misturas de ciclodextrina, uso e método de obtenção dos mesmos
ES2069330T3 (es) Derivados de hidrazona, su preparacion y uso.
AR049275A1 (es) Derivados de camptotecina conjugada en posicion 20 con antagonistas de la integrina
MX2021012708A (es) Formulaciones novedosas que comprenden melflufen.
BR112012021108A2 (pt) composições biocidas, e, uso de valerolactona e/ou de seus derivados de amida
AR055568A1 (es) Compuestos de bifenilo como antagonistas de receptores muscarinicos. procesos de obtencion y composiciones farmaceuticas.
AR044275A1 (es) Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias
AR049337A1 (es) 7-t-butoxiiminometilcamptotecina conjugada en la posicion 20 con antagonistas de la integrina
EA200300483A1 (ru) Ингаляционная композиция в виде раствора с солью тиотропия
ATE550647T1 (de) Auflösungszusammensetzung zur untersuchung von arzneistofflöslichkeit
AR038781A1 (es) Compuesto de pirazinoisoquinolina o naftaleno, composicion farmaceutica e inhibidor de pde4 que lo comprenden y sal famaceuticamente aceptable de un compuesto de pirazinoisoquinolina

Legal Events

Date Code Title Description
FB Suspension of granting procedure